TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05215249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified high-flow oxygen delivery
Description: The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
Study: NCT05483088

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection for NEPHROCLEAR CCL14 Test
Description: Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
Study: NCT05999682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apigenin
Description: Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterilized water
Description: Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
Study: NCT05482620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic walking program
Description: Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Educational sessions and usual care
Description: Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Educational sessions and usual care
Description: Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
Study: NCT05292209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG
Description: Riluzole 50mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 50 MG
Description: Riluzole 50mg tablets
Study: NCT04760496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 4 mIU/mL
Description: Oxytocin at 4 mIU/mL administrated by IV infusion controlled by pump or electric syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin 2 mIU/mL
Description: Oxytocin at 2 mIU/mL administrated by IV infusion controlled by pump or electric syringe.
Study: NCT06162052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation
Description: Technology will be used to enhance rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation
Description: Technology will be used to enhance rehabilitation.
Study: NCT06513819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique
Description: Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
Study: NCT04981327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Description: Apixaban 5 MG BID versus Apixaban 2.5 MG BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG Oral Tablet [ELIQUIS]
Description: Apixaban 5 MG BID versus Apixaban 2.5 MG BID
Study: NCT05747027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic abdominal ventral rectopexy
Description: Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS. It involves a series of small cuts in the abdomen and the use of mesh to hold the rectum in the correct position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal sacrospinous rectopexy
Description: Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment. This is a mesh-free and vaginal route procedure.
Study: NCT05602142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]CPPC PET ligand
Description: Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
Study: NCT05697497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily exercise intervention
Description: Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily exercise intervention
Description: Participants will complete four exercises each day, The first two weeks they will be instructed to complete as many repetitions as possible, each day, for 15 seconds and progressing to 30 seconds per exercise after the first two weeks. Participants are asked to increase their goal repetitions by 1 or 2 from their previous best each week. For all exercises with modifications, we will encourage participants to move to the next most difficult modification once they can do 15 repetitions of that exercise.
Study: NCT05600816

Intervention type: DEVICE
Group type: OTHER
Intervention: Pounce Venous Thrombectomy System
Description: The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
Study: NCT05250076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination.
Study: NCT06555302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
Study: NCT06464185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bispecific antibody-based combined with CAR-T cell therapy
Description: lymphocytes collection, and bispecific antibody-based therapy will be performed after successful Lymphocytes collection: Obinutuzumab:1000mg, cycle 1 day 1(C1D1) ,IV.~Glofitamab: 2.5 mg, C1D8; 10 mg,C1D15 ; 30 mg,C2D1 and C3D1, IV. It can be combined with other Immunization therapy during the use of bispecific antibodies according to the patient's condition.~On C4D1, the patient will be pretreated with fludarabine and cyclophosphamide (FC) regimen, and then infused with CART cells at a specific dose of 4 \* 1000000/Kg. Bispecific antibody maintenance therapy will be initiated on month 1/2/3 after CART infusion. In Phase1 bispecific maintenance therapy will be divided into three dose groups, using a 3 + 3 dose escalation design. In Phase 2, bispecific maintenance therapy will be used at the MTD dose of Phase 1.
Study: NCT06495047

Intervention type: DRUG
Intervention: Long-acting bronchodilator therapy (LABD)
Description: Long-acting inhaler therapy

Intervention type: DRUG
Intervention: Short-acting bronchodilator therapy (SABD)
Description: Short-acting inhaler therapy
Study: NCT06103357

Intervention type: OTHER
Intervention: blood sample collection
Description: Before and after angioplasty, blood samples upstream and downstream of the coronary lesion will be taken, arterial sampling at the aortic root level will be performed, and peripheral venous blood will be collected.
Study: NCT05734625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
Study: NCT05782699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP monitoring during tilt testing
Description: BP measure at various times during tilt testing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP monitoring during tilt testing
Description: BP measure at various times during tilt testing
Study: NCT06157645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolene mesh
Description: Application of mesh onlay post stoma closure
Study: NCT04604652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD1801 (BUDCA)
Description: HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
Study: NCT05406947

Intervention type: OTHER
Intervention: Prospective observational study, no intervention
Description: Prospective observational study, no intervention

Intervention type: OTHER
Intervention: Prospective observational study, no intervention
Description: Prospective observational study, no intervention

Intervention type: OTHER
Intervention: Prospective observational study, no intervention
Description: Prospective observational study, no intervention
Study: NCT05680857

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product containing marine collagen peptide and Coenzyme Q10.
Description: Product containing marine collagen peptide and Coenzyme Q10.
Study: NCT05734625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection
Description: Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection
Description: Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
Study: NCT06290167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 360° media
Description: sessions with head mounted display in hospital and sessions with tablet at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: sessions of TAU rehabilitation in hospital and sessions TAU rehabilitation at home

Intervention type: OTHER
Group type: OTHER
Intervention: In hospital sessions
Description: sessions will be carried out under the supervision of a therapist

Intervention type: OTHER
Group type: OTHER
Intervention: at home sessions
Description: sessions will be carried out without the supervision of a therapist

Intervention type: OTHER
Group type: OTHER
Intervention: Mild Cognitive Impairment
Description: half of this group will perform the protocol with 360° videos and the other half will perform the TAU

Intervention type: OTHER
Group type: OTHER
Intervention: Subjective Memory Complain
Description: half of this group will perform the protocol with 360° videos and the other half will perform the TAU
Study: NCT05875753

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-FS PET/CT
Description: Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration.
Study: NCT05019612

Intervention type: PROCEDURE
Intervention: Laparoscopy: A minimal invasive surgery
Description: A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
Study: NCT03448666

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
Study: NCT06543446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD implantation
Description: Surgical implant of ICD device
Study: NCT05745987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavarian Nordic smallpox vaccine
Description: A single dose of the Bavarian Nordic smallpox vaccine will be given at baseline.
Study: NCT04756843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quad-helix
Description: Fixed orthodontic appliance
Study: NCT05745987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid VI Polysaccharide Vaccine Injectable Solution
Description: A single dose of the typhoid vaccine will be given at baseline.
Study: NCT05677802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Undergo medical cart review

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Management Therapy
Description: Receive biobehavioral stress reduction intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05497349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukocyte Rich- PRP injection
Description: Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
Study: NCT05497349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte Poor- PRP injection
Description: Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
Study: NCT05675943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-COVID-19 Antibody SA55 for Injection
Description: After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Anti-COVID-19 Antibody SA55 for Injection
Description: After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
Study: NCT05975515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft /Bone graft/ Customized HA
Description: Soft tissue management and augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft /Bone graft/ Customized HA
Description: Soft tissue management and augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft /Bone graft/ Customized HA
Description: Soft tissue management and augmentation
Study: NCT05279898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Monitoring
Description: Perioperative monitoring, MMGA guided by EEG for intervention group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Intraoperative bilateral PIFB block with 20 mL of 0.2% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision (total of 40mL) PIFB on postoperative day 1 (provided they are extubated or getting ready to be extubated) to help with mobilization (for intervention group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Intraoperative intermittent bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intraoperative infusion
Study: NCT06493721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clear Aligner Treatment
Description: Clear aligner therapy to treat incisors crowding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clear Aligner Treatment
Description: Clear aligner therapy to treat incisors crowding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Apply clear aligner therapy with low level laser application on incisors
Study: NCT05421234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic test and sperm analysis
Description: Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test.
Study: NCT04326478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Enrolled children in the intervention arm of this study will receive a single weight-based dose of azithromycin (20 mg/kg, to a maximum dose of 1 gram) administered by a trained study nurse within 12 hours of a member of their household testing positive for cholera.